Electric vehicles (EVs) have revolutionized the automotive industry by offering an environmentally friendly alternative to ...

In 2022, Camzyos won FDA approval to treat certain patients with oHCM. BMS hadn’t given much fanfare to its drug's potential expansion into nHCM leading up to the readout, although the ODYSSEY ...

The US FDA has cleared the first-in-class tyrosine kinase 2 (Tyk2) inhibitor as Sotyktu, and BMS says it now plans to launch the new drug later this month, aiming to mount a challenge to Amgen's $ ...

BMS said it will launch Cobenfy within the next few weeks and has set a price of $1,850 per month for the medicine, which is considerably more than the current, largely generic array of ...

Emmys Commentary (Updated: April 17, 2025): The clock is ticking on the 2024-25 Emmy eligibility window, and HBO/Max is making a final sprint to the finish line, with two of its most celebrated ...

BMS was hoping to gain a label expansion for Camzyos based on the Phase III trial. Image credit: Shutterstock /Tada Images. Bristol Myers Squibb’s (BMS) Phase III trial investigating Camzyos ...

The late-stage stumble makes Camzyos’ label expansion into non-obstructive HCM “highly unlikely,” the analysts said. BMS did not present specific data in the news release, only revealing that Camzyos ...

This project aims to empower users to lead a healthier and safer lifestyle.

Gesture-based RC car controller using ESP32-S3, BLE, LSM6DSO IMU, OLED display, and LiPo battery with USB-C charging.